GlassScriptPhysician profile
Andrew T Johnson
NPI 1497045553
$22,243.55
in general payments reported to CMS, 2019-2025
79 companies · $3,243 in 2025
The $3,243 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,918 · 2020: $2,496 · 2021: $3,668 · 2022: $2,450 · 2023: $4,470 · 2024: $3,998 · 2025: $3,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,577 · Consulting Fee: $1,943 · Long Term Medical Supply Or Device Loan: $881 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,577.38 |
| Consulting Fee | $1,942.50 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $310.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,021.42 | 2019-2025 | Enhertu, Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $2,051.46 | 2019-2025 | |
| Seagen INC. | $1,807.31 | 2019-2023 | Adcetris, Padcev, Tivdak |
| Merck Sharp & Dohme LLC | $1,264.74 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $1,162.66 | 2019-2025 | |
| Celgene Corporation | $866.04 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $824.53 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $756.12 | 2019-2025 | Opdivo |
| Incyte Corporation | $696.58 | 2019-2025 | Jakafi, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $694.64 | 2019-2025 | Enhertu |
| Abbvie INC. | $623.99 | 2019-2025 | |
| Exelixis INC. | $474.17 | 2019-2025 | Cabometyx |
| Eisai INC. | $461.01 | 2019-2025 | |
| Genzyme Corporation | $407.70 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $400.99 | 2019-2023 | Imbruvica |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $382.57 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Astellas Pharma US INC | $372.52 | 2019-2025 | Xtandi, Padcev |
| Regeneron Healthcare Solutions, INC. | $363.57 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $335.11 | 2019-2025 | |
| Lilly USA, LLC | $318.36 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $288.91 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $284.94 | 2019-2025 | Alunbrig, Iclusig, Fruzaqla |
| Array Biopharma INC | $276.41 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $269.24 | 2019-2025 | |
| Amgen INC. | $250.77 | 2019-2022 | |
| Gilead Sciences, INC. | $227.00 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $223.48 | 2019-2025 | Zoladex, Xermelo |
| Octapharma USA, INC. | $212.37 | 2020-2021 | |
| Emd Serono, INC. | $193.41 | 2020-2025 | Bavencio |
| Rigel Pharmaceuticals, INC. | $180.09 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Puma Biotechnology, INC. | $170.02 | 2021-2025 | |
| Stemline Therapeutics INC. | $131.28 | 2020-2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.85 | 2019-2023 | Gilotrif |
| Epizyme, INC. | $114.69 | 2020-2022 | |
| Acrotech Biopharma INC. | $112.64 | 2021-2023 | Beleodaq |
| Alexion Pharmaceuticals, INC. | $107.18 | 2021-2025 | Ultomiris |
| Kite Pharma, INC. | $94.51 | 2020-2025 | Yescarta |
| Blueprint Medicines Corporation | $91.21 | 2020-2023 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $91.12 | 2021-2024 | Qinlock |
| Kyowa Kirin, INC. | $78.45 | 2020-2024 | Poteligeo |
| Aveo Pharmaceuticals, INC. | $70.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $68.72 | 2019-2024 | Odomzo, Yonsa |
| Caris Mpi, INC. | $64.62 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $63.56 | 2019-2023 | |
| Foundation Medicine, INC. | $62.47 | 2022-2023 | Foundationone Liquid Cdx, Foundationone Cdx |
| Karyopharm Therapeutics INC. | $60.79 | 2020-2025 | Xpovio |
| Coherus Oncology, INC. | $60.60 | 2020-2024 | |
| Geron Corporation | $58.59 | 2024-2025 | Rytelo |
| Beigene USA, INC. | $58.28 | 2020-2024 | Brukinsa |
| Dova Pharmaceuticals | $54.79 | 2020-2021 | |
| Sobi, INC | $54.05 | 2024-2025 | |
| Tempus Ai, INC | $51.53 | 2024-2025 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $51.09 | 2021-2025 | Pyrukynd |
| Servier Pharmaceuticals LLC | $51.00 | 2022-2024 | |
| Pharmaessentia USA Corporation | $41.60 | 2023-2025 | Besremi |
| Tolmar Pharmaceuticals, INC. | $40.33 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $39.44 | 2020 | |
| Beone Medicines USA, INC. | $37.70 | 2025 | Tevimbra, Brukinsa |
| Myovant Sciences INC. | $37.56 | 2021 | |
| Acceleron Pharma, INC. | $36.69 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $29.69 | 2025 | Clonoseq |
| Verastem, INC. | $28.50 | 2019 | |
| Recordati_rare_diseases_inc. | $28.31 | 2025 | Enjaymo |
| Sumitomo Pharma America, INC. | $24.26 | 2024 | Orgovyx |
| Genmab U.S., INC. | $23.54 | 2024 | Epkinly |
| Cti Biopharma Corp. | $23.31 | 2023 | Vonjo |
| Otsuka America Pharmaceutical, INC. | $23.26 | 2019 | |
| Mirati Therapeutics, INC. | $22.82 | 2024 | Krazati |
| Adc Therapeutics America, INC. | $21.20 | 2025 | |
| Mylan Institutional INC. | $20.54 | 2020 | |
| Azurity Pharmaceuticals, INC. | $19.98 | 2025 | Danziten |
| Morphosys, US INC. | $19.64 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.82 | 2025 | Myrisk |
| Heron Therapeutics, INC. | $18.73 | 2019 | |
| Tesaro, INC. | $17.09 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.96 | 2021 | |
| Macrogenics, INC. | $14.35 | 2022 | |
| Secura Bio, INC. | $9.79 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.